Clinical Trial Update: Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ponatinib hydrochloride in patients with advanced biliary cancer harboring FGFR2 fusions; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cancer
• Malignant Hepatobiliary Neoplasm

Drugs mentioned

• ponatinib hydrochloride (ponatinib)

Snippet

Sponsor: Mayo Clinic | Conditions: Malignant Hepatobiliary Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2019-08-06